Early development of the metabolic syndrome after chemotherapy for testicular cancer

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 749-755

  de Haas, E C ^a   Altena, R ^a   Boezen, H M ^a   Zwart, N ^a   Smit, A J ^a   Bakker, S J L ^a   van Roon, A M ^a   Postma, A ^a   Wolffenbuttel, B H R ^a   Hoekstra, H J ^a   van Leeuwen, F E ^a   Sleijfer, D T ^a   Gietema, J A ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cancer survivors; Cisplatin; Hypogonadism; Metabolic syndrome; Testicular cancer; Vascular damage

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; TESTOSTERONE; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CARDIOVASCULAR RISK; CAROTID ARTERY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG TARGETING; FOLLOW UP; GONAD FUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TESTIS CANCER; THROMBOSIS; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOVASCULAR DISEASES; CISPLATIN; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OVERWEIGHT; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 84874555886     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds527     Document Type: Article

References (38)

1. van den Belt-Dusebout AW, Nuver J, de Wit R et al.. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24: 467-475.
2. Huddart RA, Norman A, Shahidi M et al.. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513-1523.
3. Nuver J, Smit AJ, Sleijfer DT et al.. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40: 701-706.
4. Sagstuen H, Aass N, Fossa○ SD et al.. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23: 4980-4990.
5. Meinardi MT, Gietema JA, van der Graaf WT et al..Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-1732.
6. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
7. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
8. Oterdoom LH, de Vries APJ, Gansevoort RT et al..; Fasting insulin modifies the relation between age and renal function. Nephrol Dial Transplant ;2007; 22: 1587-1592.
9. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D et al.. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008; 168: 897-905.
10. Brouwer CAJ, Postma A, Vonk JM et al..Systolic and diastolic dysfunction in childhood cancer survivors. Eur J Cancer 2011; 47: 2453-2462.
11. Kuczmarski RJ, Flegal KM, Campbell SM et al.. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994; 272: 205-211.
12. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. 1993 Guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Hypertension 1993; 22: 392-403.
13. Grundy SM, Cleeman JI, Daniels SR et al.. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
14. Nuver J, Smit AJ, Sleijfer DTh et al.. Left ventricular and cardiac autonomic function in survivors of testicular cancer. Eur J Clin Invest 2005; 35: 99-103.
15. Haugnes HS, Wethal T, Aass N et al.. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28: 4649-4657.
16. Gietema JA, Sleijfer DTh, Willemse PHB et al.. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992; 116: 709-715.
17. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591.
18. Nuver J, Smit AJ, Wolffenbuttel BHR et al.. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23: 3718-3725.
19. Haugnes HS, Aass N, Fossa○ SD et al.. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18: 241-248.
20. Laaksonen DE, Niskanen L, Punnonen K et al.. Testosterone and sex hormonebinding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-1041.
21. Kupelian V, Page ST, Araujo AB et al.. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843-850.
22. Haring R, Völzke H, Felix SB et al.. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 2009; 58: 2027-2031.
23. Yeap BB, Chubb SAP, Hyde Z et al.. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study. Eur J Endocrinol 2009; 161: 591-598.
24. Van Gaal LF, Mertens IL, de Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
25. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007; 14: 55-61.
26. Lorenz MW, Markus HS, Bots ML et al.. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and metaanalysis. Circulation 2007; 115: 459-467.
27. Katsube Y, Saro H, Naka M et al.. Decreased baroreflex sensitivity in patients with stable coronary artery disease is correlated with the severity of coronary narrowing. Am J Cardiol 1996; 78: 1007-1010.
28. Gianaros PJ, Jennings JR, Olafsson GB et al.. Greater intima-media thickness in the carotid bulb is associated with reduced baroreflex sensitivity. Am J Hypertens 2002; 15: 486-491.
29. Dirix LY, Libura M, Libura J et al.. In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs 1997; 8: 859-868.
30. Ito H, Okafuji T, Suzuki T. Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats. Heart Vessels 1995; 10: 178-184.
31. Nuver J, de Haas EC, van Zweeden M et al.. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010; 23: 247-253.
32. Gietema JA, Meinardi MT, Messerschmidt J et al.. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355: 1075-1076.
33. Brouwers EEM, Huitema ADR, Beijnen JH et al.. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 2008; 8: 7.
34. Jung HS, Myung SK, Kim BS et al.. ;Metabolic syndrome in adult cancer survivors: a meta-analysis. Diabetes Res Clin Pract ;2012; 95: 275-282.
35. Redig AJ, Munshi HG. Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy. Am J Med 2010; 123: 87.e1-87.e6.
36. Braga-Brasaria M, Dobs AS, Muller DC et al.. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-3983.
37. Thomson CA, Thompson PA, Wright-Bea J et al.. Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy. J WomensHealth 2009; 18: 2041-2047.
38. Clements A, Gao B, Yeap SH et al.. ;Metformin in prostate cancer: two for the price of one. Ann Oncol ;2011; 22: 2556-2560.